These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


240 related items for PubMed ID: 2885642

  • 1. Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever.
    Clegg JC, Lloyd G.
    Lancet; 1987 Jul 25; 2(8552):186-8. PubMed ID: 2885642
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus.
    Djavani M, Yin C, Lukashevich IS, Rodas J, Rai SK, Salvato MS.
    J Hum Virol; 2001 Jul 25; 4(2):103-8. PubMed ID: 11437313
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
    Cashman KA, Wilkinson ER, Wollen SE, Shamblin JD, Zelko JM, Bearss JJ, Zeng X, Broderick KE, Schmaljohn CS.
    Hum Vaccin Immunother; 2017 Dec 02; 13(12):3010-3019. PubMed ID: 29135337
    [Abstract] [Full Text] [Related]

  • 7. Towards a human Lassa fever vaccine.
    Fisher-Hoch SP, McCormick JB.
    Rev Med Virol; 2001 Dec 02; 11(5):331-41. PubMed ID: 11590670
    [Abstract] [Full Text] [Related]

  • 8. A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region.
    Cai Y, Iwasaki M, Motooka D, Liu DX, Yu S, Cooper K, Hart R, Adams R, Burdette T, Postnikova EN, Kurtz J, St Claire M, Ye C, Kuhn JH, Martínez-Sobrido L, de la Torre JC.
    mBio; 2020 Mar 24; 11(2):. PubMed ID: 32209677
    [Abstract] [Full Text] [Related]

  • 9. [The localization and preliminary characteristics of antigenic sites (B epitopes) in the nucleocapsid protein of the Lassa virus].
    Vladyko AS, Bystrova SI, Malakhova IV, Kunitskaia LIa, Lemeshko NN, Kras'ko AG, Kozhich AT, Lukashevich IS.
    Vopr Virusol; 1993 Mar 24; 38(1):30-4. PubMed ID: 7521097
    [Abstract] [Full Text] [Related]

  • 10. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D, Mire C, Rosenke K, Feldmann F, Haddock E, Geisbert T, Feldmann H.
    PLoS Negl Trop Dis; 2015 Apr 24; 9(4):e0003736. PubMed ID: 25884628
    [Abstract] [Full Text] [Related]

  • 11. A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model.
    Kennedy EM, Dowall SD, Salguero FJ, Yeates P, Aram M, Hewson R.
    Vaccine; 2019 Aug 23; 37(36):5404-5413. PubMed ID: 31331770
    [Abstract] [Full Text] [Related]

  • 12. Expression of the Lassa virus nucleocapsid protein in insect cells infected with a recombinant baculovirus: application to diagnostic assays for Lassa virus infection.
    Barber GN, Clegg JC, Lloyd G.
    J Gen Virol; 1990 Jan 23; 71 ( Pt 1)():19-28. PubMed ID: 2406367
    [Abstract] [Full Text] [Related]

  • 13. Possible approaches to a vaccine against Lassa fever.
    Clegg JC.
    Trans R Soc Trop Med Hyg; 1984 Jan 23; 78(3):307-10. PubMed ID: 6464128
    [No Abstract] [Full Text] [Related]

  • 14. [Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever].
    Firsova IV, Shatokhina IV, Borisevich IV, Evseev AA, Maksimov VA, Pantiukhov VB, Khmelev AL.
    Vopr Virusol; 2003 Jan 23; 48(6):43-5. PubMed ID: 14708232
    [Abstract] [Full Text] [Related]

  • 15. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity.
    Carrion R, Patterson JL, Johnson C, Gonzales M, Moreira CR, Ticer A, Brasky K, Hubbard GB, Moshkoff D, Zapata J, Salvato MS, Lukashevich IS.
    Vaccine; 2007 May 16; 25(20):4093-102. PubMed ID: 17360080
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins.
    Carnec X, Mateo M, Page A, Reynard S, Hortion J, Picard C, Yekwa E, Barrot L, Barron S, Vallve A, Raoul H, Carbonnelle C, Ferron F, Baize S.
    J Virol; 2018 Jun 15; 92(12):. PubMed ID: 29593043
    [Abstract] [Full Text] [Related]

  • 18. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.
    Marzi A, Feldmann F, Geisbert TW, Feldmann H, Safronetz D.
    Emerg Infect Dis; 2015 Feb 15; 21(2):305-7. PubMed ID: 25625358
    [Abstract] [Full Text] [Related]

  • 19. Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies.
    Hufert FT, Lüdke W, Schmitz H.
    Arch Virol; 1989 Feb 15; 106(3-4):201-12. PubMed ID: 2476109
    [Abstract] [Full Text] [Related]

  • 20. Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein.
    Djavani M, Yin C, Xia L, Lukashevich IS, Pauza CD, Salvato MS.
    Vaccine; 2000 Feb 14; 18(15):1543-54. PubMed ID: 10618553
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.